PARP1 and neoplasm: On the other hand, immune activation by PARP‐1 inhibitors induces DNA damage that results in tumor cells producing more mutations and neoantigens, allowing them to be recognized and attacked by the immune system, thus achieving anticancer effects.[10] The first‐generation PARP‐1 inhibitors, based on the nicotinamide structure, incorporated electron‐donating groups or bioisosteres to develop analogs like 3‐aminobenzamide (3‐AB), enhancing intermolecular interactions and inhibition efficacy.